Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259230 · ClinicalTrials.gov registry record
Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis
A clinical trial of Hemophagocytic Lymphohistiocytosis, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT03259230 is a study of Hemophagocytic Lymphohistiocytosis that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 40 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03259230, a study of Hemophagocytic Lymphohistiocytosis, has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
Conditions Studied
Interventions
- OTHER Data Collection
- OTHER Blood Draws
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2016-10-13 |
| Est. Completion | 2020-01-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259230
The ClinicalTrials.gov registry entry for NCT03259230 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Orphan Biovitrum, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hemophagocytic Lymphohistiocytosis appearing as the primary indexed condition, and to 2 interventions - of which Data Collection is the first listed.
NCT03259230 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03259230 about?
NCT03259230 is a clinical study titled "Evaluation of IFNγ and Inflammatory Mediators in Patients With Malignancy-Associated Hemophagocytic Lymphohistiocytosis". This observational study is designed to determine the levels of pro-inflammatory markers in patients diagnosed with M-HLH, and to assess whether the cytokine profiles bear an IFNγ signature.
What is the current status of trial NCT03259230?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2016-10-13. Estimated completion is 2020-01-29.
What conditions does trial NCT03259230 study?
This clinical trial studies the following conditions: Hemophagocytic Lymphohistiocytosis.
What interventions are being tested in trial NCT03259230?
The interventions under investigation include: Data Collection (OTHER), Blood Draws (OTHER).
Who is sponsoring clinical trial NCT03259230?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03259230 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophagocytic Lymphohistiocytosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.